Association Between Circulating BDNF Levels and Cardioembolic Strokes in Patients Treated for Ischemic Stroke
- Acute Ischemic Stroke
At a glance
- Phase
- Phase not stated
- Study type
- Observational
- Sponsor
- Centre Hospitalier Universitaire Dijon
- Enrolment target
- 150
- Started
- 23 September 2026
- Main results due
- September 2031
- Study sites
- 1
- Registry updated
- 25 September 2026
Can you take part?
- Aged 18 years and over.
- Open to any sex.
- You need the condition being studied — healthy volunteers are not accepted.
These are the headline rules only. Every study has a longer list, and whether you are eligible is decided by the research team at the site — never by this page.
Read the full eligibility criteria
Inclusion Criteria: * Individuals who provided informed consent * Diagnosis of acute ischemic stroke confirmed by brain imaging (CT or MRI) * Patient admitted to the USINV of the Department of General, Vascular, and Degenerative Neurology at the Dijon Bourgogne University Hospital during the inclusion period * Underwent a combined cardiac and brain CT scan within 24 hours of admission for stroke Exclusion Criteria: * A person subject to a legal protective measure (guardianship, conservatorship) * A person subject to a judicial safeguard measure * A pregnant woman, a woman who has recently given birth, or a breastfeeding woman * An adult who is legally incapacitated or unable to give consent, * A minor
What this study is about
In the sponsor’s own words, from the registry.
Atrial fibrillation (AF) is associated with serious complications, including embolic strokes, heart failure, and mortality. Disruption of normal blood flow in the atrium, particularly in the context of an endocardium predisposed to thrombosis, increases the risk of thrombus formation. Once dislodged from the atrial cavity and traveling to the cerebral arteries, these thrombi can cause a cardioembolic stroke. The main risk factors for atrial cardiomyopathy (ACM) and AF are metabolic syndrome and aging.
ACM is a condition that is difficult to diagnose because it is not clearly defined, except through histological analysis. Guided by the results of our experimental approaches, the investigators aim to address this challenge by examining ACM through the lens of one of its complications: cardioembolic stroke. BDNF (Brain-Derived Neurotrophic Factor) is a neurotrophic factor involved in inflammatory and metabolic processes that may play a key role in the development of these complications.
This study explores the association between circulating levels of BDNF and the morphological and metabolic characteristics of ACM, as assessed by cardiac and brain imaging studies
Study sites(1)
Chu Dijon Bourgogne
Dijon, France
Recruiting
Showing 1 of 1 sites. 1 of the 1 site on this study is recruiting right now — a site can stop enrolling while the study as a whole is still open.
Source: ClinicalTrials.gov record NCT07624396. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.
Not the right study?
Answer three questions and see the studies recruiting near you, in plain language.
Find a study for me